



Commit to Human Health
Commit to Human Life
Commit to Human Future

XIANGBEI WELMAN PHARMACEUTICAL CO.,LTD.


Xiangbei Welman Pharmaceutical Co., Ltd.



Welman Profile



Strategically cover several important segments



All manufacturing lines feature worldwide leading level of automation control

Annual production capacity:

- 150 million units of penicillins powder for injection
- 80 million units of cephalosporins powder for injection
- 150 million tablets of oral preparations

Welman Profile



**Specialize in Antibiotics Resistant to ‘Superbugs’ with Anti-drug Genes.
Dedicate to R&D Innovation and Quality Management.**


9	Chinese Innovative Drug Certificates
10	Production Lines covering powder for injection, tablets and hard capsules of penicillins and cephalosporins; common solid dosage forms, anti-cancer drugs, psychiatric drugs, diabetes drugs
28	Owned and licensed IP Rights
30	Penicillins and cephalosporins antibiotics products
60	Drug Approval Certificates
357.5 million	Investment in antibiotic production base in Liuyang Biopharmaceutical Industrial Zone, Hunan, China.

Welman Profile

ACTION LANDSCAPE : Beta lactam antibiotic


Total Active Drugs **105** Total Companies **149**

CURRENT DEVELOPMENT STATUS



Filters

COMPANIES




Filters

ACTION LANDSCAPE : Beta lactamase inhibitor


Total Active Drugs **64** Total Companies **69**

CURRENT DEVELOPMENT STATUS



Filters

COMPANIES



Filters

Xiangbei Welman Pharmaceuticals is a leading company in development of beta-lactam antibiotics & beta-lactamase inhibitor products which are promising in fighting “Superbugs” (i.e. bacteria with multiple antimicrobial resistance) .

** out of 149 pharmaceutical companies worldwide, in developing beta-lactam antibiotics products, Pfizer Inc. ranks No.1; Shionogi & Co.,Ltd. together with Xiangbei Welman Pharma rank No.2. (Source: Cortellis, July 2017)*

** In developing beta-lactamase inhibitor products, Pfizer Inc. ranks No.1; Wockhardt Ltd. together with Xiangbei Welman Pharma rank No.2. (Source: Cortellis, July 2017)*

Welman Profile: R&D



Welman attaches great importance to R & D system and training of high-end medicine talents .Direct R&D input accounts averagely **10%** of avenues.

Policy: renew manufacturing pipeline by developing, pre-researching and reserving a set of products respectively

R & D mode: collaborate internally and externally, industrially and academically, with universities and enterprises.

Achievements:

- 2 new medicines of national class 1, 3 new medicines of national class 3, 7 clinical trial approval of new antibiotics compound preparations
- Strategic drugs under research include oral medication equoyitol to treat diabetes (TCM Class I)、 raw materials and formulations of Psychotropic drug modafinil (Chemical 3.1) and bromhexine Hydrochloride dispersing tablets (Chemical 3.2). The latter two has finished cilinical study and are in process of getting approval.

Welman Profile: R&D




Industrial and Academic R&D Cooperation Projects

Project Name	Partner
Wellman New Drug Development Center, China Pharmaceutical University,	China Pharmaceutical University
National Life Science and Technical Personnel Training Base	China Pharmaceutical University
Wellman Pharmaceutical Joint Laboratory, Central South University, College of Pharmacy	Central South University
Wellman Pharmaceutical Engineering Master Station, Central South University	Central South University,
Wellman Pharmacy Master Station, Central South University	Central South University,
Wellman Outstanding Scholarship, College of Pharmacy, Ji'nan University	Ji'nan University
Wellman Outstanding Graduate Scholarship, Medical School, Nanjing University	Nanjing University
Wellman Scholarship for Outstanding Graduate, Suzhou University	Suzhou University
Wellman Scholarship for Outstanding Students, Zhongshan University	Zhongshan University
Wellman Scholarship, Central South University,	Central South University,
Wellman Scholarship for Outstanding Graduate, Sichuan University	Sichuan University
Welman Reward for Doctors in Department of Infection, Chinese Medical Doctor Association (CMDA)	Chinese Medical Doctor Association (CMDA)

Welman Profile: Marketing & Sales



The sales network of Welman covers 32 major cities of 31 provinces in China, generating tax on profit nearly 100 million and revenues averaging several hundreds million RMB.



Welman Profile : IPRs



System of Intellectual Property : Patents ,Trademarks , Copyrights , Know-how

29 IPs of inventions owned by Welman, **1** authorized IP of invention

156 Registered trademarks and **4** authorized trademarks

67 Copyright protection of Product identification , product brochures, new drug submission files, analytical methods .

A bright blue sky with white clouds and a flock of birds flying in the distance.

Thank You!